“Consistently, the combination of mechlorethamine plus romidepsin resulted in downregulation of STAT5 phosphorylation in romidepsin-sensitive cell lines and primary SS samples, but not in romidepsin-resistant tumors.”
“Here, we show synergistic anti-lymphoma effects of romidepsin in combination with mechlorethamine , an alkylating agent, in CTCL cell lines and primary samples with strong antitumor effects in an in vivo model of SS.”
“Overall, these results support a role for romidepsin plus mechlorethamine in combination in the treatment of CTCL and uncover a previously unrecognized role for JAK-STAT signaling in the response to romidepsin and romidepsin-based combination therapies in SS.”